News >

Veliparib Falls Short in Phase III NSCLC, TNBC Trials

Jason M. Broderick @jasoncology
Published: Thursday, Apr 20, 2017

Gary Gordon, MD, PhD

Gary Gordon, MD, PhD

Veliparib failed to meet the primary endpoint in phase III non–small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) trials, according to AbbVie, the company developing the PARP inhibitor.

The safety profile of veliparib plus carboplatin/paclitaxel was comparable to that of carboplatin/paclitaxel alone. All-grade adverse events (AEs) occurred in 100% of the veliparib arm and 97.9% of the placebo arm.

The most common nonhematologic AEs in the veliparib versus the placebo arm included alopecia (66.7% vs 57.3%), arthralgia (36.6% vs 32.3%), back pain (30.1% vs 22.9%), constipation (38.7% vs 29.2%), diarrhea (38.7% vs 28.1%), fatigue (50.5% vs 59.4%), headache (35.5% vs 32.3%), and peripheral neuropathy (68.8% vs 59.4%).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x